Technical analysis of KALA BIO, Inc. (KALA): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R.
Price Performance
| 1 month | -41.96% |
| 3 months | -85.55% |
| Year-to-date | -98.12% |
| 1 year | -99.94% |
| 3 years | -99.90% |
| 5 years | -99.99% |
52-Week Range
| 52-week High | $1030.00 |
| 52-week Low | $0.49 |
| Avg Volume (90d) | 270K |
Technical Indicators
| SMA 50 | $0.77 |
| SMA 200 | $12.44 |
| 30-day Volatility (annualised) | 107.9% |
| Price vs SMA 50 | -32.3% |
| Price vs SMA 200 | -95.8% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $39.00 | |
| 2025-11 | $48.31 | +23.9% |
| 2025-12 | $27.80 | -42.5% |
| 2026-01 | $26.50 | -4.7% |
| 2026-02 | $19.00 | -28.3% |
| 2026-03 | $8.65 | -54.5% |
| 2026-04 | $5.26 | -39.2% |
| 2026-05 | $2.23 | -57.6% |
| 2026-06 | $1.73 | -22.4% |
| 2026-07 | $0.76 | -56.3% |
| 2026-08 | $0.67 | -11.0% |
| 2026-09 | $0.52 | -22.5% |
Price
| Price | $0.52 |
| Market Cap | $10M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.00 |
| EV / EBITDA | -1.09 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 6.88 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -60.75 |